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The potential of Human Biomonitoring (HBM) in exposure characterisation and risk assessment is well
established in the scientiﬁc HBM community and regulatory arena by many publications. The European
Environment and Health Strategy as well as the Environment and Health Action Plan 2004–2010 of the
European Commission recognised the value of HBM and the relevance and importance of coordination of
HBM programmes in Europe. Based on existing and planned HBM projects and programmes of work and
capabilities in Europe the Seventh Framework Programme (FP 7) funded COPHES (COnsortium to Per-
form Human Biomonitoring on a European Scale) to advance and improve comparability of HBM data
across Europe. The pilot study protocol was tested in 17 European countries in the DEMOCOPHES fea-
sibility study (DEMOnstration of a study to COordinate and Perform Human biomonitoring on a Eur-
opean Scale) cofunded (50%) under the LIFEþ programme of the European Commission. The potential of
HBM in supporting and evaluating policy making (including e.g. REACH) and in awareness raising on
environmental health, should signiﬁcantly advance the process towards a fully operational, continuous,
sustainable and scientiﬁcally based EU HBM programme. From a number of stakeholder activities during
the past 10 years and the national engagement, a framework for sustainable HBM structure in Europe is
recommended involving national institutions within environment, health and food as well as European
institutions such as ECHA, EEA, and EFSA. An economic frame with shared cost implications for national
and European institutions is suggested beneﬁtting from the capacity building set up by COPHES/DE-
MOCOPHES.
& 2014 Elsevier Inc. All rights reserved.1. Introduction
Increasing public environmental health interest and awareness
has developed over the past 20 years from concerns of the (gen-
eral) public, regulators, and non-governmental organisations
(NGOs) about rising incidence rates for a number of important
diseases, and the potential risks of exposure to environmental
stressors (e.g. endocrine disruptors) for human reproduction and
health. As a consequence a better understanding of the health and
environment relationships is asked for, and requests for collective
as well as individual data on exposure that could be used for risk
assessment and management are constantly growing.
To reduce potential risks a considerable number of regulatory
measures has been taken on EU level in particular for chemicals,
which requires health risk assessment for workers and the general
population. A better understanding of determinants of health is
also required to improve effective health promotion and disease
preventive policies and to reduce public health costs.
Human biomonitoring (HBM) surveys can be used to establish
baseline levels of chemicals in the investigated population, to
compare exposures and to help identify priority chemicals for
which further action should be taken. An important ﬁeld is use of
HBM in policy surveillance, identiﬁcation of new risks, and bene-
ﬁts for risk assessment and chemicals regulation (Kolossa-Gehring,
2012).
HBM is a growing discipline used for exposure and risk as-
sessment in environmental and occupational health (Manno et al.,
2010; Angerer, 2012; Knudsen and Merlo, 2012). In environmental
health, a number of studies have been performed with newborns
(Casas et al., 2013; Leventakou et al., 2014; Pedersen et al., 2013;
Papadopoulou et al., 2013)), children (Frederiksen et al., 2014;
Mørck et al., 2014a; Conrad et al., 2010), and adults with classical
biomarkers of exposure (Bevan et al., 2013; De Felip et al., 2014) as
well as promising markers of effect (Stayner et al., 2014; Pedersen
et al., 2013; Merlo et al., 2014; Silins and Hogberg, 2011) and new
‘omics′ techniques (Knudsen and Merlo, 2012; Hebels et al., 2013;
Vrijheid et al., 2014; Kyrtopoulos, 2013; Vineis et al., 2013).
Several EU ﬁnanced projects have developed and validated
human biomarkers such as the PHIME (Public Health Impact of
long-term, low-level Mixed element Exposure in susceptiblelicy recommendations and
es. (2014), http://dx.doi.orgpopulation strata) integrated project, Newgeneris (Newborns and
Genotoxic exposure risks: Development and application of bio-
markers of dietary exposure to genotoxic and immunotoxic che-
micals and of biomarkers of early effects, using mother-child birth
cohorts and biobanks) programme (Merlo et al., 2009), or the
ECNIS (Environmental Cancer Risk, Nutrition and Individual Sus-
ceptibility) network of excellence or OBELIX (Obesogenic endo-
crine disrupting chemicals: linking prenatal exposure to the de-
velopment of obesity later in life).
HBM activities in Canada, France, Belgium (Flanders), Germany,
India, and Romania have been described in the textbook issued in
2011 (Knudsen and Merlo, 2012) when activities were also known
in countries as Austria (Hohenblum et al., 2012), Czech Republic
(Cerná et al., 2012), Poland (Jakubowski and Trzcinka-Ochocka,
2005), Sweden (Bergkvist et al., 2010), and US (CDC, 2010).
HBM data can be used to determine whether the level of ex-
posure of the public, special subgroups or individuals are accep-
table or whether measures need to be taken. HBM can be used to
monitor whether bans on substances or restrictions on their use
have led to a decrease in exposure, and HBM can provide in-
formation on substance properties and potential risks.
But European countries differ largely in their priority setting,
environmental concerns, registration governance, culture and
ethics, as well as in their resources in terms of budget, manpower
and expertise and there is a severe lack of comparable data and
coherent approach within the European Union. Fragmentation
between countries and studies however, strongly limits the use of
results for European health impact assessments and cross-border
comparison as well as the evaluation of key European chemicals,
and customers policies. To allow a better use of the data and to
evaluations at European scale and international scale, harmoni-
sation of activities has been considered to be required urgently
(Joas et al., 2012).
Therefore in 2003 the European Commission and the European
Member States (MS) started efforts to construct an efﬁcient HBM
framework across the European Union within the European En-
vironment & Health Strategy (SCALE) and in particular the En-
vironment and Health Action Plan for Europe (EHAPE 2004–2010).
As a result a preparatory feasibility study (ESBIO) was conducted
from 2005–2007 (Viso et al., 2009; Joas et al., 2012) that discussedcost implications for a more sustainable framework for European
/10.1016/j.envres.2014.10.012i
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collaboration with the EU Parliament and a consultative forum
(CF), that was set up in 2002 as the stakeholder consultation body
for the development of SCALE, and that continued to provide input
into the implementation of the EHAPE. The consultative forum
consisted of environment and health representatives of EU
Member States as well as experts from NGOs, industry and EU and
international bodies (European Food Safety Authority (EFSA),
World Health Organisation (WHO), etc.). Due to the close colla-
borationwith the consultative forum and in particular with the MS
experts the ﬁrst key steps for a coordinated approach could be
achieved. Based on the work of ESBIO (Reis et al., 2007), discus-
sions within the CF and a number of supportive reports such as the
midterm evaluation report of the EHAPE (Commission of the
European Communities, 2007), the pilot phase for harmonised
HBM in Europe was started with the Consortium to Perform Hu-
man Biomonitoring on a European Scale (COPHES) in 2009, that
laid the basis for a ﬁrst feasibility study DEMOCOPHES (DEMOn-
stration of a study to COordinate and Perform Human biomoni-
toring on a European Scale) starting in 2010.
The main objective of COPHES/DEMOCOPHES was the devel-
opment of a functional framework for a coherent approach to HBM
in Europe in order to achieve comparable HBM data that support
environmental, health and chemicals policy (Joas et al., 2012).
Major results from COPHES/DEMOCOPHES are detailed in this
special volume.
This paper discusses the results of the policy work that was
destined to develop recommendations for a strategy for future
HBM activities in the EU, to elaborate a draft concept for a sus-
tainable EU HBM infrastructure supporting the future im-
plementation of HBM and its use as a tool to inform policy making
with comparable and reliable results that are necessary for Eur-
opean policy making and global initiatives. It further aimed at
providing a ﬁrst estimate of costs, beneﬁts and resources needed
for a sustainable HBM initiative.2. Methods
The development of the proposal for a sustainable EU HBM
infrastructure built on knowledge gained from ESBIO and on in-
tensive stakeholder consultation. In addition, it built on input from
Member States, European authorities (Commission and agencies
such as EFSA, the European Chemicals Agency (ECHA), and the
European Environment Agency (EEA) and of the World Health
Organisation Europe (WHO-Europe) regarding requirements and
needs related to HBM and experiences with costs, beneﬁts and its
practical application as a surveillance tool in policy making.
The project team on policy support asked for and welcomed
feedback from environment and health authorities at a national
level in all Member States, Directorates General of the European
Commission for Health, Environment, Occupation and Enterprise
as well as its related European Agencies, and of the WHO Eur-
opean Centre for Environment and Health. In addition, input was
provided by invited stakeholders from the European non-gov-
ernmental organisation Health and Environment Alliance (HEAL),
from the European association of chemical industry (CEFIC), from
international well established national HBM programmes namely
the National Health and Nutrition Survey in the USA and the Ca-
nadian Health Measures Survey (CHMS) in Canada, and from re-
lated European research projects. Invitation was based on political
relevance and thematic expertise in environmental or environ-
mental health issues.Please cite this article as: Joas, A., et al., Policy recommendations and
human biomonitoring surveys. Environ. Res. (2014), http://dx.doi.org2.1. Data collection for identiﬁcation of needs and priorities
Collection of policy needs was based on literature search, eva-
luation of existing regulation and infrastructure and stakeholder
involvement. Information collected via these means was com-
plemented by evaluation of personal interviews.
2.1.1. Identiﬁcation of needs and priorities of Member States and
study leaders via electronic questionnaire
Key needs and currently existing practise, expectations, bene-
ﬁts, operational issues, and remaining questions related to the use
of HBM as a policy tool have been collected via questionnaires
from competent authorities (Ministries of Health and Ministries of
Environment) and other stakeholders (scientiﬁc study leaders,
study leaders of the DEMOCOPHES pilot study and the experts
responsible for carrying out the pilot study in the individual
countries) and via literature search. The survey with questions
about current use of HBM, expectations, beneﬁts, operational is-
sues, and key needs related to the use of HBM as policy tool was
disseminated to several hundred institutions in 28 European
Member States and adjacent countries. Responses were received
from more than 100 experts from the institutions listed in
(Table 1).
2.1.2. Identiﬁcation of needs and priorities by means of consultations
with scientiﬁc experts, policy makers and stakeholders
For further information exchange on priorities and needs,
promotion of a common understanding of the potential role of
HBM and preparation of the concept for a sustainable HBM fra-
mework in Europe, the COPHES work package leaders on policy
advice and other Work package leaders participated in interna-
tional conferences targeted on HBM allowed to promote the Eur-
opean harmonisationcos
/10The Fifth Ministerial Conference on Environment and Health
“Protecting children′s health in a changing environment” or-
ganised by the World Health Organisation (WHO) Europe in
March 2010 which resulted in the Parma Declaration on En-
vironment and Health The International Conference on Human Biomonitoring
–“Political beneﬁts – scientiﬁc challenges”, organised by
the German Ministry of Environment (BMU) and the
Federal Environment Agency (UBA) in Berlin, in September
2010. The European Conference “From human biomonitoring to pol-
icy: a sustainable ‘marriage′ between health and environment”
organised by the Environment, Nature Energy Department of
the Flemish government under the Belgian Presidency of the
European Union in October 2010
Three dedicated stakeholder workshops have been organised
by the COPHES team on policy advice during the course of 2011
and 2012 (see http://www.eu-hbm.info/cophes/project-work-
packages/wp8-support-eu-hbm-programme). Meeting results
have been compiled in project deliverables.1. An EU Decision Makers Meeting on the use of Human Biomo-
nitoring for policy making that took place in Munich on 4 May
2011.2. A European Authorities Scientiﬁc Expert Meeting on the use of
Human Biomonitoring as a policy tool on mid and long-term
perspective (5–15 years) held in Brussels on 2 February 2012.3. An international conference From Human Biomonitoring to
European and national policies: meeting the Member States
(MS) representatives organised in Paris at the Ministry of
Health on 17 September 2012.t implications for a more sustainable framework for European
.1016/j.envres.2014.10.012i
Table 1
List of participating European Research Institutions and Authorities.
Institution Country
KU Leuven-University of Leuven BE
Centre for Health Education and Disease Prevention LT
Centre for Research in Environmental Epidemiology (CREAL) ES
Centre of Public Research CRP-Gabriel Lippmann (Lab) LU
CHEMTOX (Lab) FR
Community of Madrid, Environmental Health Services ES
Copenhagen University Hospital, Dept of Growth and Reproduction DK
Environment Agency Austria (Umweltbundesamt) AT
Environmental Health Centre (RO) RO
Environmental Specimen Bank for Human Tissues DE
Estonian Institute for Health Development (NIHD) EE
FABER Foundation CH
Federal Environment Agency (UBA) DE
Federal Ministry for Environment, Nature Conservation, Building and
Nuclear Safety
DE
Federal Ministry of Labour, Social Affairs and Consumer Protection AT
Federal Ofﬁce for the Environment CH
Federal Ofﬁce of Public Health CH
Federal Public Health Institute DE
Federal Public Service, Health, Food chain safety and Environment BE
Federal Statistic Ofﬁce CH
Flemish Institute for Technological Research (VITO) BE
Free University of Brussels (VUB/ULB), Department of analytical and
environmental chemistry
BE
French Institute for Public Health Surveillance (InVS) FR
Hainaut Health Surveillance BE
Health & Safety Laboratory (Lab) UK
Health Austria GmbH AT
Health Services Executive IE
Helmholtz Centre for Environmental Research UFZ DE
Initiativ Liewensufank LU
Institute for Medical Investigations of the Sea Hospital (IMIM) &
Autonomous University of Barcelona
ES
Institute for Medical Research and Occupational Health HR
Institute for Work and Health (Lab) CH
INSTITUTO DE SALUD CARLOS III ES
Integrated BioBank of Luxembourg (IBBL) LU
National Institute for Health, Italy (ISS) IT
Kaunas University of Medicine, Institute of Cardiology LT
Medical University Vienna AT
National Institute for Health Development EE
National Institute for Public Health and the Environment (RIVM) NL
National Institute of Environmental Health HU
National Institute of Public Health CZ
Newcastle University UK
Nofer Institute of Occupational Medicine PL
Norwegian Institute of Public Health NO
Ofﬁce for the regional public health authority in Košice SK
Private University for Health Sciences, Medical Informatics and
Technology (UMIT), Institute of Public Health
AT
Public Health Authority of the SR SK
Public Health England (PHE). The Health Protection Agency, Centre
for radiation, chemicals and environmental hazards
UK
Public Health Institute Maribor (Lab) SI
Regional Authority of Public Health SK
Regional Institute for Hygiene Antwerp (PIH) BE
RESEARCH AND EDUCATIONAL INSTITUTE OF CHILD HEALTH CY
Research Centre for Public Health ( CIEC ) LU
Research Institute of Child Nutrition Dortmund DE
Ruhr-University Bochum, Department for Hygiene, Social and En-
vironmental Medicine
DE
Ruhr-University Bochum, Institute for Prevention and Occupational
Medicine (IPA)
DE
Scientiﬁc Institute for Public Health (WIV-ISP) BE
Slovak Medical University, Department of Toxic Organic Pollutants SK
Spanish Research National Council ES
State General Laboratory CY
State Health Agency of Baden-Württemberg DE
State Ofﬁce for consumer protection, Saxony-Anhalt DE
Statistic Austria AT
Swiss Centre for Applied Human Toxicology (Lab) CH
Federal Ofﬁce of Public Health CH
Swiss Federal Ofﬁce for material science (Empa) CH
University Rovira i Virgili (Lab) ES
University College London UK
Table 1 (continued )
Institution Country
University Medical Centre Ljubljana, Institute of Clinical Chemistry
and Biochemistry (Lab)
SI
University of Copenhagen DK
University of Erlangen, Institute of Occupational, Social and En-
vironmental Medicine ( IPASUM)
DE
University of Las Palmas de Gran Canaria ES
University of Liege, Department of Toxicology BE
University of Lisbon, Institute of Preventive Medicine PT
University of Ljubljana, Jožef Stefan Institute SI
University of Nicosia CY
University of Southern Denmark DE
University of Stockholm, Institute of Environmental Medicine, Kar-
olinska Institute
SE
University of Vienna, Department of Medical Genetics AT
University of Vienna, Institute of Environmental Health AT
University of Vienna, Institute of Nutritional Sciences AT
University of Vienna, Institute of Public Health AT
University of Vilnius LT
Vytautas Magnus University Kaunas; Department for Environmental
Studies
LT
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Please cite this article as: Joas, A., et al., Policy recommendations and
human biomonitoring surveys. Environ. Res. (2014), http://dx.doi.orgInvitations to participate in the discussion were sent to differ-
ent departments (units) of the Directions General of Enterprise,
Employment, Environment, Health and Consumers and Research
and Innovation, the Joint Research Centre (JRC), as well as to
European Agencies (ECHA, EEA, EFSA, EMA, OSHA) and Scientiﬁc
Committees. Overall 17 Commission services actively supported
the process by participating in the meetings (Table 2).
In addition, various departments of the Ministries of Health
and of Environment as well as corresponding national agencies or
institutes were contacted in all 28 European Member States plus
associated European countries such as Norway, Switzerland, and
Iceland Representatives from 12 countries participated in the
discussion process. Bilateral contacts and information exchange
took place with the chemicals Unit at the European Commission
Directorate General for Environment (March 2011 and 2012, July
2012), with the Risks assessment and Health information Units at
the Directorate General for Health and Consumers at the European
Commission (March 2012, September 2012) and with public health
agencies in Canada and the USA (October 2011, April 2012, Sep
2012) as well as with Ministries of Health and Environment in
interested Member States (e.g. France, Germany).
COPHES work package on policy support supported the de-
velopment of the WHO mercury survey (Egorov et al., 2013) and
close consultations and exchange were organised with the WHO
Regional Ofﬁce for Europe, European Centre for Environment and
Health, Bonn Ofﬁce (Sep 2011, Feb 2012, April 2012, Sep 2012, Oct
2012).
Furthermore, intensive exchange was realised with related
European research projects such as the European Health Ex-
amination Surveys (EHES) via exchange with the Finnish National
Institute for Health and Welfare (THL) as Project Management
(March 2010, 2011, 2012, April 2012) or ERA-ENVHEALTH (June
2012) via the French agency for food, environmental and occu-
pational health safety (ANSES) as coordinating beneﬁciary. Finally,
continued exchange was sought with PHIME, EN-
VIROGENOMARKERS, and ECNIS via the COPHES work package
leader on horizon scanning.
The COPHES team on policy advice participated in the public
consultations related to the drafting of the 7th Environment Action
Plan (June 2012), drafted a vision paper for future use of HBM and
a number of discussion documents for better integration of HBM
in a number of public health and environmental policies, partici-
pated in international conferences and ﬁnal meetings of EHES andcost implications for a more sustainable framework for European
/10.1016/j.envres.2014.10.012i
Table 2
List of participating European Institutions and WHO.
Institution Active participation
DG Enterprise Unit G.1, Chemicals-REACH
Unit G.2, Chemicals-Classiﬁcation and Labelling
DG Environment Unit D.3, Chemicals, Biocides and Nanomaterials
Unit F.4, Research and Innovation
European Commission General Directorate Health and Consumers Unit B.3 Product and Service safety
Unit C.2, Health information
Unit C.3, Health threats
Unit D.3, Risk assessment
European Agency for Health and Consumers (EAHC)
Scientiﬁc Committee on Health and Environmental Risks (SCHER)
Scientiﬁc Committee on Consumer Safety (SCCS)
Scientiﬁc Committee on Emerging and Newly Identiﬁed Health Risks (SCENIHR)
DG Research Unit I.4, Climate Change and natural hazards
EEA, European Environment Agency– Unit IEA1, Integrated Environmental Assessments-Major integrated assessments
JRC, Joint Research Centre- Chemical Assessment and Testing (CAT) Unit
Systems toxicology
EFSA, European Food Safety Authority Unit of Contaminants (CONTAM)
WHO WHO European Centre for Environment and Health
A. Joas et al. / Environmental Research ∎ (∎∎∎∎) ∎∎∎–∎∎∎ 5ERA-ENVHEALTH and participated at the Final project meeting of
the pilot projects and the international conference “Human Bio-
monitoring (HBM) Linking Environment to Health and Supporting
Policy” under the Cypriot presidency in Cyprus 22–24 October
2012.
Throughout the whole process consensus was sought between
the participating stakeholders and comments and suggestions
were taken into account as far as possible in the elaboration of the
concept. It has to be mentioned however, that the outcome of the
discussion process was inﬂuenced by the active participation in
the process.
2.2. Methodology for elaboration of concept for sustainable organi-
sation and structure of an EU HBM network in Europe
The elaboration of the concept was based on the reported
needs of policy makers as well as experiences of countries with
established HBM programmes such as France (Fréry et al., 2012),
Czech Republic (Cerna et al., 2012) and Germany (Kolossa-Gehring
et al., 2012), Slovenia (Perharic and Vracko, 2012) of regions such
as Flanders (Schoeters et al., 2012),and other European countries.
Comprehensive HBM programmes from other regions in the world
namely USA and Canada were particularly taken into account. In
addition, experiences and recommendations from the pilot project
on harmonisation of health examination surveys in Europe (EHES)
were taken into account and potential synergies in the light of
associated costs were considered (see Section 3.3.3).
The proposal for sustainable infrastructure for HBM in Europe
and a ﬁrst estimation of related costs was made (Section 3.4). This
includes links to the existing regulatory frameworks (Section 3.5)
and recommendations for coordinated support to policy decision
making (Section 3.6).
2.3. Methodology for estimation of costs and resources, needed for a
sustainable long-term European HBM
Based on the experiences from DEMOCOPHES and the concept
of a sustainable framework data collection and calculation of
budgetary ranges have been structured into the following
categories:P
hEuropean Platform for systematic selection of HBM candidate
substances European Decision making processlease cite this article as: Joas, A., et al., Policy recommendations and
uman biomonitoring surveys. Environ. Res. (2014), http://dx.doi.orgcos
/10The national surveillance infrastructure with national Focal
Point, regional and local executing units, qualiﬁed laboratories,
national data interpretation units, and national communication
units European HBM implementation network developing guidance
on study protocol, quality assurance system for laboratory data,
data management and interpretation unit, and communication
as well as Financial and organisational mechanisms
 Review mechanisms and continuous improvement of the
network
For the estimation of costs and resources needed each of the
above mentioned aspects has been considered in a minimal as
well as in a maximal scenario. Man power and related costs have
been calculated on average salaries. Finally, each parameter has
been checked for its sensitivity.
Based on the sustainable framework structure, the existing data
and Member State experiences an Excel tool has been developed
to centralize and efﬁciently store and make use of the data. The
Excel ﬁle is composed of 14 data sheets. All sheets are connected
to one sheet comprising an overview on the overall costs.
In general, the sheets present three main columns, namely
“Investment costs”, “Recurrent expenditure” and “Variable costs”.
The column “Investment costs” summarises the costs needed as
non-recurrent expenses to e.g. establish structures, studies or
personnel/positions. “Recurrent expenditures” calculates un-
avoidable and periodical costs, e.g. costs for the maintenance of
the platform, a website, etc. “Variable costs” comprises the costs
that directly depend on decisions taken, e.g. number and type of
substances, number of Member States participating, number of
samples, etc.
The columns were further divided into the sub categories “time
expenditure”, “personnel costs” and “material expenditure”. The
sheets allow the input of information for single countries (Member
States) as well as the other involved bodies. The rationale behind
this procedure is to be able to collect data as detailed as possible to
have justiﬁable results in the end.
2.3.1. Data collection
Background data for the calculation have been collected from
DEMOCOPHES participants and national HBM programmes. As
these data are sensitive, none of the data given in this report can
be traced back to its origin. All 17 DEMOCOPHES implementing
partners were contacted and condensed budgetary informationt implications for a more sustainable framework for European
.1016/j.envres.2014.10.012i
Table 3
DEMOCOPHES partners approached for ﬁnancial information.
Participant
country
MS Supporting ministry Performing institutions




Cyprus CY Health Governmental Institute
Germany DE Environment Governmental institute
Denmark DK Environment, Food,
Health
University
Poland PL Health Governmental institute
Romania RO Health Private
Slovenia SI Health Governmental institute
Spain ES Environment Governmental institute
Hungary HU Health and
environment
Governmental institute
Sweden SE Environment University
United Kingdom UK Health Governmental institute
Portugal PT Health Governmental institute
Ad hoc CH Health Governmental institute
Czech Republic CZ Health Governmental institute
Slovakia SK Health Governmental institute
Luxembourg LU Health Private
Ireland IE Health Governmental institute
Adhoc FR Health Governmental institute
Adhoc AU Environment Governmental institute
Adhoc CROA Health Governmental institute
Ad hoc NO Health Governmental institute
A. Joas et al. / Environmental Research ∎ (∎∎∎∎) ∎∎∎–∎∎∎6was provided by 12 of the 17 countries (i.e. CH, CZ, DE, DK, IE, LU,
PT, RO, SE, SI, SK, UK). As the budget calculations for the pilot study
are estimates only beneﬁciaries involved in the pilot study were
asked for an adjustment of the delivered data, including in-kind
contributions.
In parallel, the timesheets of all DEMOCOPHES implementing
partners have been evaluated for efforts related to operational
HBM framework, sampling, recruitment and sample collection,
sample handling, chemical analysis and storing (including bio-
banking), data analysis and integrated interpretation as well as
communication and dissemination and management (Table 3).
Beneﬁciaries with ongoing or ﬁnalised national HBM studies
have been asked to kindly provide ﬁnancial and time efforts ac-
cordingly. The request also included information about number of
samples and substances covered in the national studies. For a
plausibility check, budgetary information and experiences from
other countries namely USA and Canada have been taken into
account.
For the estimations it was assumed that an EU HBM network
will perform one measurement round each year. As it is not rea-
listic to calculate costs at this stage exactly for a selected number
of chemicals and samples, calculations are done by personnel costs
and estimated overall efforts. Costs for chemical analysis of in-
dividual samples are not included in the estimate. Such individual
costs have been investigated in detail in 2004 in preparation of the
pilot phase and are less than €20-50 per samples for heavy metalsTable 4
Estimation of resource needs.
Task (per country) Person Month p.a. (PM)
Operational framework 14.7
Sampling and Recruitment& Sample collection 11.9
Sample handling, quality assurance and analysis 14.8
Data analysis and integrated interpretation 4.4
Communication & Dissemination 5.1
Management 3.3
p.a.¼per annum (per year).
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cent information from WHO (World Health Organisation, 2012). In
addition, synergies can be used for a number of substances.
2.3.2. Resource estimates
For managing incoming input and ad-hoc suggestions for can-
didate substances in the (electronic) suggestion platform we es-
timated resource needs of a half time up to a full time person per
year based on experiences from other regulations and conventions
(secretariat).
For the decision committee we based our calculation on mini-
mum and maximum scenario for an expert group. For the mini-
mum scenario the calculation is based on 10 experts and 2 annual
meetings. The maximum scenario is based on an expert group of
40 experts and 4 meetings per year. For the meetings we assumed
two meeting days and three days preparation and follow up each.
For travel costs we calculated an average of €300 per travel day per
person. These ﬁgures include decision making on European scale.
They do not include costs for scientiﬁc committees elaborating
substance dossiers. This will allow participation of at least one
delegate per Member State on average, and based on experience
from other conventions, allows for up to 10 decisions per meeting.
For the European coordination platform as part of the im-
plementation and enforcement network we based calculations on
a best estimate of 5–10 full time equivalents per year. Based on
experiences from the pilot study this will enable further devel-
opment of guidance for study design/protocol, data analysis and
reporting, communication, interpretation and translation into
policy exchange and on potential data storage. It does not com-
prise establishment and maintenance of QA/QC systems. For the
HBM implementation and enforcement network the resource
needs have been estimated based on the minimum and maximum
resource needs from the pilot phase. A small reduction factor was
introduced due to the fact that efforts to build up routines and
structures as during the pilot phase will not be necessary anymore
(Table 4).
A part time position up to one full and one part time position is
estimated for the operational framework on national level per
campaign based on input from the pilot phase. For sampling, re-
cruitment and sample collection a half time up to two full time
positions are assumed. This parameter is highly sensitive de-
pending on the number of samples as well as on the study design
and the experience of the staff involved. The same personnel ef-
forts are assumed for sample handling and chemical analysis,
again being highly sensitive depending on the number of chemi-
cals measured. For data analysis and the integrated interpretation
three person months per year up to a full time equivalent is as-
sumed. Depending on the data volume this is again a highly sen-
sitive parameter. For the communication again three person
months per year up to a full time equivalent is assumed.
As best estimate for all involved staff (senior and junior sci-
entist, ﬁeld workers, administrative staff) an average salary ofRange estimated PM p.a. min estimated PM p.a. max
from to
7.7 19.1 6 18
1.1 21.4 6 24
3.9 31.6 6 24
1.1 6.5 3 12
1.6 11.7 3 12
1.1 5.9
cost implications for a more sustainable framework for European
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Table 5
Overview on average salary of scientiﬁc and administrative staff in 14 countries
participating in pilot phase by country in Euro.
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sumed for the calculation of personnel costs (Table 5). It needs to
be considered that this ﬁgure not only presents an average for all
28 European countries and for different education levels. While
sampling might be performed by a nurse with low salary data
interpretation might be carried out by a highly paid specialist.3. Results and discussion
3.1. Current status and remaining priorities and needs
COPHES has established the ﬁrst Europe wide harmonised
protocol for HBM surveillance of the European population and
together with DEMOCOPHES, provided results about the feasibility
of a harmonised sampling and analysis approach including capa-
city building and knowledge transfer, but is limited with regard to
the selected set of substances, matrices and sample size. On the
way towards a ﬁnal sustainable and powerful European wide hu-
man biomonitoring survey framework comparable to the Amer-
ican NHANES (Calafat, 2012) or the Canadian Health Measures
Survey (Haines and Murray, 2012) further research and develop-
ment work will be needed in order to reach a self-supporting
concept as suggested and described in this report.
Priorities for the future comprise, in particular, the identiﬁca-
tion of appropriate biomarkers including the development of va-
lidated analytical (large-throughput) methods, and the develop-
ment of a European approach for the derivation of statistically
based reference values and health based HBM guidance values.
Other aspects are appropriate information, education, commu-
nication and dissemination of study results, data storage and
sample/data sharing.
3.2. Needs to be covered and limitations to respect
During the stakeholder consultation, an improved use of
monitoring data generated within the European Union including
better access for secondary use and better comparability was
emphasised as an important objective in European environmental
and health policies.
3.2.1. Comparable, accessible and timely monitoring data
Comparable monitoring data on European scale are considered
as key parameter for use of HBM as policy tool. Scientist and policy
makers repeatedly highlighted the need for comparable data
generated throughout Europe, and it was agreed that there is ba-
sically only one reliable approach, which is a harmonised study
protocol. The speciﬁc request for additional HBM data to follow up
uncertainties regarding future exposure, expressed in the opinion
of the European Committee for Risk Assessment (RAC) from 15
June 2012, related to the ﬁrst ever proposed restriction of four
classiﬁed phthalates (DEHP, DBP, BBP, and DIBP) in articles underPlease cite this article as: Joas, A., et al., Policy recommendations and
human biomonitoring surveys. Environ. Res. (2014), http://dx.doi.orgREACH. This, highlights the importance of this tool for decision
making on chemicals and product regulation.
Priorities in policy making are a fast response to questions and
the provision of timely answers on needs for acute actions. In or-
der to ensure an efﬁcient use of HBM data for policy making and
evaluation, European authorities and Member State authorities
need free and timely access to all monitoring data required for
data interpretation. For this reason there is a need for an estab-
lished infrastructure and overall guidance that can quickly react to
arising threats and that is cross sectional in structure. In the light
of technology and science development and newly arising ques-
tions over time, the secondary use of data and samples is a second
priority for European Commission Services. In this context, it was
clariﬁed that constraints to access and secondary use of HBM data
need to be solved in the light of European data needs.
3.2.2. Mechanisms of priority substances and appropriate
biomarkers
In the light of the huge and constantly increasing number of
chemicals on the European market, and the several thousands of
substances to be registered or authorised under REACH and as-
sessed for potential risks, it was stressed that HBM will only be
able to ﬁll its role in risk assessment if appropriate procedures to
identify substances of priority for monitoring via HBM can be es-
tablished. It was highlighted in expert discussions that in addition
to actively selected substances from regulatory processes it will be
necessary to foresee non-target HBM screening to identify
“emerging” pollutants of concern based on exposure and health
risks to the general population. In addition, substitutes (of banned
substances) will need to be tested in order to reliably assess their
risks. It was highlighted by DG ENV representatives that from the
chemicals unit point of view:1.cos
/10The highest priority for HBM from the point of view of Com-
mission services is its potential use in risk assessment of mix-
ture toxicity, as it is a unique instrument for assessment of the
total burden of exposure of a population at a given time.2. A second priority was seen in the ﬁeld of REACH (substances of
high and of less concern) where risk assessment is foreseen in
the prioritisation and authorisation process.
3.2.3. Validated analytical methods for biomarker determination
Reliable and validated methods for sampling and analysis of
selected biomarkers are a crucial element and selection criterion
for the application of HBM. Chemical–analytical methods need to
be speciﬁc and sensitive enough to detect environmental exposure
and QA/QC systems need to be established to ensure sufﬁcient
reliability (Schindler et al., 2014; Esteban et al., this issue). As
currently HBM methods are available for only a minor share of the
100,000 chemicals on the market, policy makers and scientist
identiﬁed an urgent need to speed up the development or ad-
justment of methods in order to allow sufﬁciently fast analysis at
reasonable prices.
3.2.4. Monitoring protocols and quality assurance systems
Study protocols and study design are a key parameter for the
information and results that are generated with HBM and have
considerable implications on budget needs (Becker et al., 2013). In
addition ethical and data protection issues play an important role.
As compatible study design is considered crucial for the genera-
tion of comparable results, whilst needs and capacities of Member
States can be quite different, there is as fundamental need for a
decision structure to set standards and elements to be contained.t implications for a more sustainable framework for European
.1016/j.envres.2014.10.012i
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tion issues
From the European policy perspective it is essential to be able
to perform evaluation and interpretation of data collected in
Members States on a European scale. Information needs for policy
making were reported to comprise European average and range, or
proportion of population above a guidance or limit value, time and
spatial trends, interregional variability and aspects of environ-
mental justice. The European Commission proposal related to the
establishment of an “Information Platform for chemical monitor-
ing” considered compatible data storage systems on national level
with virtual linkage and exchange procedures managed by EEA or
JRC as important starting point towards an integrated data use.
The integration of HBM data into the virtual European platform
was considered a priority for the chemicals unit of the European
Commission Directorate General for Environment in the light of
the assessment of mixture toxicity.
Interpretation of HBM data requires a considerable amount of
additional information to allow trace back to potential sources and
to be able to estimate health risks using health based guidance
values (Angerer et al., 2011; Bevan et al., 2012; Hays and Aylward,
2012).
Interpretability of HBM results also depends on sample size and
recruitment patterns in terms of geographical and demographic
stratiﬁcation, with a population representative sample as ideal
although not mandatory (see Kolossa-Gehring et al. (2011); Fid-
dicke et al., this issue). Experts globally agree that there is need to
continue research into tools to assess the sources of exposure and
in evaluation of toxicological and health impacts of different levels
of exposure to environmental chemicals. Decisions also need to be
taken concerning use of existing options for collaboration to fur-
ther improve and increase cost-efﬁciency in terms of data man-
agement and interpretation.
Policy makers need clear information about potential risks on
national, regional or local scale and about needs for action from
the public health or environmental point of view, whereas in-
dividuals need to be informed about their personal risks. Given the
particular alerting power of HBM, responsible communication is
important and can be challenging in terms of balancing ad-
vantages and risks. In this context it is crucial to use similar
benchmarks and to provide similar messages across Europe and to
carefully balance beneﬁts and risks (see Exley et al., this issue).
3.2.6. Budgets, resources and responsibilities
In times of ﬁnancial constraints and low budgets there exist
high hurdles to fund costly programmes even if considered re-
levant. Costs of HBM surveys were hence considered a key para-
meter for its potential use as policy tool. Shared funding solutions,
prioritisation of stressors and risks, as well as optimised protocols,
and effective use of existing resources for surveillance were
highlighted as priorities and prerequisites for a continued use of
HBM. In this context it was considered important to coordinate to
the extent possible the guidance and protocols developed by na-
tional, European and international monitoring programmes/in-
itiatives. Read-across of monitoring and research results from one
country to another was suggested as another option to increase
efﬁciency and reduce costs.
Expert discussions highlighted the challenge to ﬁnd an appro-
priate funding body for HBM, given the fact that surveillance is
observational in nature and is at the interface between research,
and a considerable range of sectorial policies under responsibilities
of various ministries on European, national, regional and local le-
vel. Responsibilities are distributed to Environment, Health and
Consumers, Enterprise and Industry, Employment, Social Affairs
and Equal Opportunities as well as Research and Innovation.Please cite this article as: Joas, A., et al., Policy recommendations and
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HBM
In order to establish a European HBM programme that is
comparable to national surveys in other industrialised countries,
there is need for a sustainable structure and framework that will
allow an expansion of the scope of the pilot, the identiﬁcation of
priority areas for use and a cost-efﬁcient and targeted integration
with other existing surveillance structures, data sources and data
storing tools. To ensure consistency of Member State action over-
arching structures and responsibilities complementary to MS
systems in place and could be established on European scale.
The concept as presented in Fig. 1 could constitute a structural
framework allowing for an efﬁcient and coordinated im-
plementation and use of HBM taking into account best scientiﬁc
and economic knowledge and being open to technical progress
and methodological developments over time. Key elements are a
European structure and a decision body for harmonisation, and
coordination purposes, and elaboration of guidance. This com-
prises, in particular, the identiﬁcation of priority substances and
validated biomarkers, as well as methodologies to ensure com-
parable HBM results, to derive reference values and health based
guidance values, to interpret and communicate HBM data, and
decisions on study design, data storage and exchange, and review
procedures. A cost-efﬁcient integrated surveillance system and
network at Member State level responsible for national surveys,
and a European funding body to support technology development
and ongoing research are further key elements.
The proposed framework is ambitious and demanding in terms
of cooperation between parties involved, but examples from
overseas show the feasibility of such a scheme. They furthermore
demonstrate that such systems can be designed on a long-term
perspective, with a considerable added value for policy-making. In
addition, the framework is modular and can be established in a
stepwise approach starting from an informal information ex-
change to develop into a legally based infrastructure.
Proposed core infrastructural pillars of the framework are a
European HBM suggestion and coordination structure, a selection
procedure for the identiﬁcation and prioritisation of substances
and method development linked to existing EU law and upcoming
threat, and a HBM implementation and enforcement network
embedded in Member States.
3.3.1. EU HBM suggestion and coordination platform
A key element of the proposed structure would be a platform
designed to enable information exchange and decision making
between competent authorities of the European Union, stake-
holders and scientists. In particular, for prioritisation of substances
and biomarker development, survey design and communication
issues, and to ensure a systematic introduction of candidate sub-
stances for a risk and feasibility based selection and prioritisation
procedure.
The platform should serve to collect requirements of policy
makers and to prioritise potential candidates for European HBM
studies. It could receive automatically all substances that are
regulated to minimise use and exposure or are under discussion
for further regulation, in a similar approach like in the United
States or other States, where candidate substances are taken from
the national registries of substances of concern.
In addition, the platform should be open to nomination of
additional “ad hoc” candidates. Such nominations could be al-
lowed for each citizen in the European Union including the sci-
entiﬁc community, NGOs, public or industry – like in the United
States (see box in the upper right corner of Fig. 1), or it could be
restricted to Member State and European administration such ascost implications for a more sustainable framework for European
/10.1016/j.envres.2014.10.012i
Fig. 1. Overview on the concept for a sustainable HBM in Europe.
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and related Scientiﬁc Committees.
Rights and procedures to bring forward candidate substances to
the platform could follow procedures as established under the
Stockholm Convention and the Aarhus Protocol on POPs or under
REACH.
The European platform could be managed by one of the Eur-
opean Agencies (e.g. EEA, ECHA or JRC) and preferably would be
ﬁnanced by Commission Services. In this context it is important to
notice that a corresponding role has been discussed as well for the
“Information Platform for chemical Monitoring” planned by the
European Commission as virtual data storage and exchange plat-
form for environmental monitoring data.
3.3.2. Decision scheme for prioritisation of substances for European
HBM studies
The purpose of the decision scheme is to provide best added
value for invested efforts. Therefore the decision scheme could bePlease cite this article as: Joas, A., et al., Policy recommendations and
human biomonitoring surveys. Environ. Res. (2014), http://dx.doi.orgbased on a cost-beneﬁt investigation related to the exposure
knowledge gained. This aspect beyond many others speaks in fa-
vour of a close collaboration of environmental and public health
authorities.
Following the example of national HBM programmes we re-
commend to base prioritisation on scientiﬁc and feasibility criteria
such as health relevance and exposure risk to the general popu-
lation, costs and beneﬁts, political interest, adequate analytical
methods, and available samples. The national beneﬁt of analysing
supplementary substances of national interest should be taken
into account (Mørck et al., this issue) As decisions will be highly
complex and will need to take into consideration latest scientiﬁc
developments, decisions should be based on scientiﬁc investiga-
tions and consultations and on dossiers prepared by a scientiﬁc
committee or advisory board composed of experts from academia,
industry, and NGOs. This approach will allow the use of latest
science that supports HBM programmes. It will be important in
this phase to ensure close collaboration and feedback to Europeancost implications for a more sustainable framework for European
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areas where there are information gaps and needs.
Options to follow are the approaches used by ECHA and EFSA or
the Stockholm Convention (dossiers), or the ones established by
e.g. Germany, France or the USA (Casteleyn et al., this issue). The
German HBM group and the joint initiative with the chemical
industry could be used as an example for the design of a “fast but
scientiﬁcally sound mechanism”.
Given the ﬁnancial and administrative implications of the se-
lection procedure, ﬁnal decisions on prioritisation would need to
remain in the hands of competent authorities. Nominated Member
State experts and Commission Services and representatives of the
concerned agencies are suggested to form a Decision Committee.
A participatory approach involving stakeholder representatives,
social scientist, politician, and civil society should be considered at
this stage as well in order to ensure high acceptability (Keune
et al., 2008).
The establishment of such a Decision Committee could be
based on article 168, Para 2 Treaty on the Functioning of the
European Union (TFEU). Also the inclusion of HBM in the 7th
European Environment Action Programme or in a revised Endo-
crine disrupting chemical (EDC) strategy would give sufﬁcient le-
gal background to allow DG Environment to take initiative in this
respect. Examples that could be used as a model are e.g. the ad-
visory groups CARACAL, CASC NANO, POPRC, or the Indoor Air
working Group. In the long-term perspective it ideally might fol-
low the examples of the Stockholm Convention and REACH. An-
other option would be the establishment of a European Research
Infrastructure Consortium (ERIC).
3.3.3. The HBM implementation and enforcement network (national
and European level)
The network shall consist of an EU guidance unit for protocol
development, quality assurance, data management, data inter-
pretation, communication, translation into policy and of surveil-
lance infrastructures in the Member States with mutual data and
knowledge exchange. Clear organisation from the national (health
and/or environmental authorities) to the local level, as well as
systematic involvement of the national contact person in Eur-
opean consultations and the EU expert network is considered a
crucial element. The scientiﬁc expertise in each MS should be in-
volved in protocol development e.g. through open consultation.
3.3.3.1. National surveillance infrastructures. The majority of
Member States have established surveillance infrastructures
linked to either health or environmental authorities. In the pro-
posed concept we would recommend to fully rely on the estab-
lished infrastructure. For a smooth information ﬂow it will be
crucial to organise the infrastructure from the national to the local
level with clear responsibilities and information transfer, and to
systematically ensure involvement of the contact persons in each
Member State into European consultations and to ensure regular
personal contacts within a European network following e.g. the
example of the DEMOCOPHES “National Focal Point” (NFP).
3.3.3.2. The European HBM coordination platform. In order to en-
sure comparable monitoring data on a European scale, which is
considered as key parameter for use of HBM as policy tool, there is
a need for central coordinating tasks that help Member States in
establishing their HBM programmes in a harmonised or compa-
tible way. Such coordination tasks could include guidance and
advice on protocol development, quality standards and quality
assurance systems and data analysis and interpretation as well as
on communication, and training or knowledge exchange. Based on
the experience from the pilot phase the European coordination
platform should support exchange and prepare guidance orPlease cite this article as: Joas, A., et al., Policy recommendations and
human biomonitoring surveys. Environ. Res. (2014), http://dx.doi.orgrecommendations in particular for the following aspects where
harmonisation would be beneﬁciary:cos
/10Development and adjustment of study design/protocol
 Establishment and maintenance of QA/QC system
 European data exchange and potential data storage
 Data analysis and reporting
 Communication, interpretation and translation into policyThe European coordination platform could be part of the se-
lection platform and decision scheme and committee, or the
composition, legal basis and the structure could follow a similar
approach.
The European HBM coordination platform shall closely co-
operate and continuously take up latest scientiﬁc knowledge that
supports HBM programmes via feedback and input from the Eur-
opean and national research authorities and shall trigger further
research via identiﬁcation of needs. European study protocol unit:
Comparable and harmonised study design is considered crucial for
the generation of comparable results, whereas on the other hand
needs and capacities of Member States can be quite different. For
maximum synergies surveys will need to be integrated as far as
possible with planned and ongoing national surveillance pro-
grammes, or international activities initiated e.g. by WHO for
implementation of the Parma Declaration requirements (Egorov
et al., 2013).
The European Unit could support the integration of all these
aspects in the development of a guidance that ideally would be
ﬂexible to new demands in terms of study population, recruitment
areas, matrices and substances. Modular approaches with mini-
mum and more extended survey designs might be considered to
facilitate participation of Member States and to be able to adapt to
ﬁnancial limitations and constraints. Key aspects that should be
tackled and addressed in the guiding EU protocol are the
following:1. Best arrangement of sample size and distribution (e.g. re-
presentative regions)2. Use of and integration with existing national programmes and
data.3. Maximum coordination with guidance and protocols developed
by existing national, European and international monitoring
programmes/initiatives.
European unit for coordination of QC/QA: QC/QA aspects are
crucial to enable comparable HBM results, and hence need to be
coordinated at European scale. Whilst other national HBM pro-
gramme commonly built on central laboratories a more diversiﬁed
approach needs to be taken in the European Union in order to meet
Member State needs. This could be achieved by a Committee com-
posed of core national laboratories that jointly select reference la-
boratories for substances that have been prioritised. This committee
could integrate or build on the NORMAN network (http://www.nor
man-network.net/) established in 2005 to support exchange and
method development on emerging substances and the validation and
harmonisation of analytical methods.
European unit for data interpretation, communication and
translation of results: (DEMO)COPHES concluded that interpreta-
tion and communication of results is a most sensitive and critical
part of a European wide approach and that the high speed and
strong interaction of information ﬂows within the European Union
have major implications on communication. Conﬂicting messages
need to be avoided. Against this background guidance and re-
commendations developed at European level is considered an
important ongoing priority in communication and interpretation,
as well as for the elaboration of health based guidance values.t implications for a more sustainable framework for European
.1016/j.envres.2014.10.012i
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standards for data management and biobanking are a prerequisite
for comparable European wide interpretation and potential re-
analysis, it is considered crucial for future European HBM to es-
tablish guidance on these aspects and to establish one central data
repository, which can virtually or physically be linked to national
data bases. Based on current experiences and due to privacy issues
a central European database or biobank is not feasible. We
therefore recommend restricting EU coordination efforts to gui-
dance for data management, data analysis, sample preparation for
storage and biobank management as well as to a central in-
dependent and neutral repository for European wide analysis of
coded data, or to a virtual database linking to national repositories.
In the light of existing activities, the establishment of a European
database and information exchange platform in one of the Eur-
opean agencies (e.g. EEA, JRC), and a close collaboration with the
health information system managed by the Directorate General for
Health and Consumers is considered as a promising approach. A
ﬁrst step towards this approach is the suggested integration of the
current pilot HBM database structure into the chemicals database
currently being developed by JRC, as initiated in a meeting be-
tween (DEMO)COPHES experts and Directorate General for En-
vironment in Brussels in July 2012.
3.3.3.3. Interactions between Member States and European Institu-
tions. Besides the guidance and support function of the European
infrastructures for Member States, it is considered crucial to es-
tablish a reverse information transfer from Member States to the
European institutions. This transfer could comprise in particular
the provision of national survey data for European data bases, or
the exchange of nationally/regionally developed good practise in
study design, interpretation and communication. Such a more
individualised approach could be used as a starting point of an
intensiﬁed cooperation or could constitute a light version of a
harmonised framework.
3.3.3.4. Potential for synergies in ﬁeldwork or method develop-
ment. As Health examination (HES) and Health Information (HIS)
Surveys are population based and are collecting questionnaire data
or biological samples similar to HBM, there is an overlap to both
approaches which can be used to reduce costs of recruiting and
sampling as successfully shown on national level. Combination
with HES might be particularly beneﬁciary as participation rates
tend to be higher than with isolated HBM and biological samples
are taken together with clinical investigation and information on
health state.
As food is still an important source of exposure to a wide range
of chemicals an integration of nutrition surveys with health ex-
amination or HBM as currently performed in NHANES and some
national programme in Europe could be another option to use
synergies, and is in line with the objectives set by the European
Food Safety Authority (EFSA).
Finally we consider synergies in method development and
study design to be available from close collaboration with activ-
ities in other regions of the world and with activities organised by
WHO. National HBM surveys have been suggested by WHO Europe
as the data source for several indicators.
3.3.4. Review mechanisms and continuous improvement of the
network
In the light of a sustainable system that ideally is not spending
more money than it saves in terms of public health beneﬁts, it is
essential to focus on priority risks and to include a constant review
and optimisation mechanism, based on indicators of success and
efﬁciency.Please cite this article as: Joas, A., et al., Policy recommendations and
human biomonitoring surveys. Environ. Res. (2014), http://dx.doi.orgThe review mechanisms shall aim to collect feedback of every
HBM related action and to improve procedures continuously. This
concerns in particular prioritisation procedures, the study design,
ﬁeld work performance, laboratory work, data management and
interpretation, as well as communication. It shall include the es-
tablishment of removal/reduction criteria to target resources to
the most important needs. Such criteria could comprise the ex-
istence of a better biomarker, a clear decrease in contamination
over time or the detection of chemicals with higher risk.
The review mechanism should also cover the ongoing optimi-
sation of sample size and distribution (e.g. representative regions),
based on the requested information level. Furthermore it should
investigate and assess any upcoming options to use and integrate
with existing national programmes and data, as well as guidance
and protocols developed by national, European and international
monitoring programmes/initiatives.
An ongoing horizon scanning and exchange with academia/
research highlight any new technological and scientiﬁc develop-
ment in terms of biomarker or method development. The review
mechanism could be used also for translation of results into policy
recommendations and can trigger revisions in this ﬁeld.
3.3.5. Funding mechanisms
Costs of harmonised HBM survey are an essential parameter for
its potential use as policy tool. Budgets that can be spent are
limited and may vary depending on economic conditions. On the
other hand HBM will only be of value if repeated in regular in-
tervals to show trends over time. As a general rule it can be stated
that budgetary aspects will play an important role as a selection
criterion both for the prioritisation of substances as well as for the
study design. As costs for recruitment, sampling and analyses
differ considerably, available budget will impact on the type of
substances that can be measured, the frequency of measurements
and the number of samples that can be taken. In order to allow
ﬂexibility whilst ensuring maximum comparability European
guidance will be needed.
An annual ﬁxed budget would allow adjustments e.g. the
number of analyses by subgroups in relation to the analytical costs
and to agreements on appropriate intervals for repeated analysis
to assess time trends. Ideally Member States and European Com-
mission would agree on a ﬁxed budget, that could be spent an-
nually, and a ﬂexible set up of the guidance on study design. This
should allow reducing the number of samples or the number of
investigated substances in single countries in case of severe eco-
nomic difﬁculties without endangering the infrastructure and the
data collection for retrospective analysis. In addition, the funding
mechanism shall request best cost-quality relations and screen for
best market offers for chemical analysis.
For optimised use of available funding schemes, co-ﬁnancing
concepts for different aspects of the surveys as well as an opti-
mised combination of similar survey approaches (see use of sy-
nergies) would need to be established on bilateral or multilateral
basis on national as well as on European level. The European co-
ordination unit could establish recommendations or guidance in
this ﬁeld. Co-funding between health and environmental autho-
rities and involving where relevant other ministries, NGO and in-
dustry could in principal be considered for all aspects of HBM
survey from protocol development to communication and re-
porting. An initial suggestion based on feedback from Commission
Services is the following:1.cos
/10DG RTD: improvement of biomarkers, investigation of real-life
chemical mixtures, and investigations of the presence and
signiﬁcance of health effects, analytical method development.2. DG Environment /DG Sanco coordination tasks in line with the
subsidiarity principle.t implications for a more sustainable framework for European
.1016/j.envres.2014.10.012i
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pretation and communication on national level.
For a sustainable funding scheme it will be important to pro-
vide proof about the cost-beneﬁt of HBM for public health costs.
3.4. Budgetary requirements for a sustainable HBM framework
In the following a cost and resource calculation is provided for
a European wide HBM framework as proposed. The calculation is
based on estimates from DEMOCOPHES and national surveys, and
relates to the proposed future HBM infrastructure, and hence to a
full blown network. Figures are differentiated for the establish-
ment of a European decision making and selection platform and
for the national surveillance infrastructure and shall not be con-
sidered more than estimates. The two scenarios are based on
minimum and maximum resource needs from the pilot phase and
on experiences with coordination tasks from COPHES and ESBIO.
They are associated in part with considerable uncertainty. How-
ever, due to the experiences made in the pilot phase, both sce-
narios are realistic and imaginable for an EU HBM framework, just
depending on the importance and therefore on the dimension and
awareness of the network.
3.4.1. Costs for core European units
Based on the assumption of a European Commission perma-
nent ofﬁcial in medium salary range of EC salary Table (€8000;
range € 2769.95–16944.98) and human resources of a half time (6
person months per year) up to a full time person (12 person
months per year), annual costs for a European suggestion platform
for HBM substances can be expected to be in the range of €50,000-
100,000 per year (Table 6). It is assumed that the platform is es-
tablished within the EC.
For the Decision Committee an expert group is assumed with
different dimensions for the minimal and the maximal scenario.
Depending on number of meetings and number of experts in-
volved this ﬁgure is relatively sensitive and can inﬂuence ﬁnal
overall costs. As illustrated in Table 7 the costs would account to
roughly €90,000 per year based on a Decision Committee of 10
experts and a meeting frequency of two meetings per year, whilst
they would raise by a factor of eight to €720,000 with an Expert
Committee of 40 experts and a meeting frequency of four meet-
ings per year. In addition annual travel costs in the range of €
12,000 (40€300)–96,000 (320€300) are to be considered
based on an average of €300 per travel day per person.
Based on the experiences of COPHES a European implementa-
tion unit is estimated to entail annual budgetary needs of €
300,000–600,000 for coordination and further development of
guidance work on study design, chemical analysis, communication
and data management as illustrated in Table 8. The ﬁgure does not
comprise the costs for development of new biomarkers or analy-
tical methods.
This means that in the minimum scenario €400,000 and in the
maximum scenario annual expenses of roughly €1.4 million are to
be expected at European level. In the case of biobanking, addi-
tional costs, amounting approximately to 7,000,000 € per year,
have to be considered based on the experience of the German
Environment Specimen Bank.Table 6
Suggestion platform for substances.
Financing by whom? estimated PMa p.a. min estimated PM
Electronic Platform EC 6 12
a PM¼person month.
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Based on one measurement round each year comparable to the
DEMOCOPHES approach, budgetary needs between € 120,000 and
450,000 per year can be assumed as a best estimate at country
level (Table 9).
In this context recruitment and sampling as well as sample
handling and chemical analysis constitute the major determinants
for costs, representing more than 50% of the overall estimated
budgetary needs. For chemical analysis this share can even further
increase considerably depending on the type of substances
analysed.
With 28 Member states participating the overall costs would
hence range from €3.8 Million (minimum scenario) to €14.1Million
(maximum scenario) annually.
3.4.3. Costs of programmes established in USA and Canada
The costs of a comparable HBM approach in the United States of
America (NHANES1), funded by the US Congress, sum up to ap-
proximately 5 Million US Dollar per year. The NHANES approach
includes 10,000 samples in 30 US states in a two year cycle. The
Canadian Health Measures Survey (CHMS2) calculated an overall
sum of 35 Million Canadian Dollar for a 5 years approach, or
roughly 7 Million Dollar per year. A comparison with an estimated
annual average budget for the European Union for EU coordination
and capacity in 28 Member States of €9 Million (range €3.8–14.1)
shows that the calculation does not underestimate costs and that
cost reduction compared to the pilot phase shall be expected by
synergy of scale.
3.4.4. Cost–beneﬁts assessment for Europeanwide HBM
In the past years, discussions on the beneﬁts of HBM have been
taken place in nearly every European Member State as well as at a
European level. It is obvious that HBM is an excellent tool to assess
people′s health in an integrated way but is on the other hand also
linked to high economic efforts. Not always an immediate beneﬁt
for policy makers is obvious and available, as results need to be set
in relation to other available data or need to be considered in a
long term perspective. An EU HBM Framework would realise this
in the most efﬁcient way. Data would be comparable within the EU
and recurring data collections would allow seeing time trends and
would allow evaluating the effectiveness of policy decisions to
reduce or eliminate certain compounds in the environment. Limit
values for European citizens could be established or maintained
and exposure pathways could be identiﬁed in a uniform way. As
Paustenbach and Galbraith (2006) stated “Biomonitoring can also
reduce the uncertainty inherent within traditional exposure and
risk assessments.” A total of 14 Mio € per year for the maximal
scenario means less than 3 Cent per EU citizen per year.
3.5. Options for integration of HBM into the European regulatory
framework
The example of occupational health legislation, or of the
Stockholm Convention on POPs or of national legislation in e.g.
Flanders and Slovenia illustrate how integration of HBM or mon-
itoring in the regulatory framework promotes and ensures data
generation. A mandatory data collection scheme is also considered
a prerequisite to ensure the allocation of the necessary fundingp.a. max costs in € per PM costs in € min costs in € max Sensitivity
8000 48,000 96,000 low
cost implications for a more sustainable framework for European
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Table 7
Decision committee assuming expert group.




average daily rate per expert
[€]
costs in € min costs in € max Sensitivity
Decision committee EC countries/EC 100 800 900 90,000 720,000 medium
Travel costs EC countries/EC 12,000 96,000 low
a (10 experts, 2 annual two-day meetings, 3 days preparation each¼1010 PDs).
b (40 experts, 4 annual two-day meetings, 3 days preparation each¼4020 PDs).
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this reason it was considered as crucial in recent expert discussion
to integrate HBM in key legal documents, thematic strategies, or
action programmes in the policy ﬁelds such as Chemicals Legis-
lation, Plant Protection Products (PPP), Biocides, Endocrine dis-
ruptors (EDC Strategy), or mercury (global mercury strategy) or
the 7th Environment Action Programme. In this context a shared
or joint responsibility between involved DGs, Agencies and
Member States was considered important. Given the multi-re-
sponsibility of involved authorities and the need to integrate sta-
keholders and science, there is broad agreement about a frame-
work that determines how to apply and where to integrate the
different elements.
3.5.1. European or International Policies suitable for integration of
HBM
By now only the Stockholm Convention on persistent Organic
Pollutants, the Aarhus Protocol, and the European Regulation on
Persistent Organic Pollutants (EC) no. 850/2004 as well as the
Directive 98/24/EC “Chemical Agents Directive as supplemented
by Directives 2000/39/EC and 2006/15/EC for protection of work-
ers at workplace are explicitly requesting HBM.
In addition, there is a large number of other legislation, reg-
ulating emissions, production or use of substances or aiming at
minimised exposures, which does not mention the use of HBM as
alert or surveillance instrument, but relate to substances or pro-
duct groups which are suspected to potentially cause environ-
mental and health risks or are focussing on health prevention in
general without a particular focus on environmental determinants.
This legislation and these policy strategies have the potential to
incorporate recommendation for the use of HBM, as they relate to
aspects where association between environment and health is
considered. Major examples of such substance/source oriented





huThe Reach regulation (EC) no. 1907/2006
2. The Community strategy for endocrine disruptors
3. The Food Contact Materials Regulation no. (EC) 1935/2004 and
the Regulation on Food Additives no. (EC) 1333/2008
4. The Toy Safety Directive 2009/48/EC
5. Regulation (EC) no. 1223/2009 on cosmetic products
6. The Community Strategy Concerning Mercury as reviewed
COM/2010/0723 ﬁnal
7. The Water Framework Directive (WFD) 2000/60/EC together










EC countries/EC 60 120 5000
ease cite this article as: Joas, A., et al., Policy recommendations and cost
man biomonitoring surveys. Environ. Res. (2014), http://dx.doi.org/10.Surface waters 2008/105/EC and the Groundwater Directive
2006/118/EC8. The Air Quality Directive 2008/50/EC
9. Biocidal Products Regulation no. (EC) 528/2012
10. Plant Protection Products Regulation (PPP) (EC) no. 1107/2009
11. Environment Action Programmes
12. Public Health ProgrammesFinally it is worth mentioning recent priorities on assessment
of mixture toxicity which might be associated to HBM. The draft
communication from the Commission to the Council prepared
suggests several options in order to improve risk assessment.
These include:1. Ad-hoc working group for coordination of data collection and
integrated assessment2. Review of monitoring data currently collected in research and
under EU legislation3. More coherent generation, collection, storage and use of che-
mical monitoring data
3.5.2. Added value that harmonised HBM could provide to EU
policies
European wide HBM can contribute both to European en-
vironment and public health policies. In environmental policies
harmonised HBM can in particular respond to key objectives as
illustrated in Fig. 2.
In public health policies the responsibility of the European
Commission is focussing on risk assessment in food and feed
safety, legislation on veterinary medicinal products, plant protec-
tion products (pesticides), biocides and consumer products.
HBM can contribute to the objectives of the current European
Public Health Programme (Health for Growth) due to the fact that
it can contribute to a proper risk assessment and safety evaluation
of all substance groups regulated in the food and feed legislation
and it can close the gap between environmental data and health
outcomes, and provide the necessary data for potential environ-
mental determinants of major chronic diseases, and can support
and follow up preventive actions. Furthermore it can contribute to
monitoring, and early warning for cross-border health threats, in
particular regarding chemical incidents and environmental/an-
thropogenic threats, and in combination with toxicological as-
sessments it can contribute to health information and knowledge
to contribute to evidence-based decision making.PM Total costs in €
min
Total costs in €
max
Sensitivity
300,000 600,000 high depending on dimen-
sion of network
implications for a more sustainable framework for European
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Table 9
National HBM implementation and enforcement network (per country).
Tasks Estimated PM p.a. Costs in €
min max Average PM
salary
Costs in € min Costs in € max Sensitivity
operational framework 6 18 5000 30,000 90,000 medium
sampling and recruitment and sample
collection
6 24 5000 30,000 120,000 high depending on number of samples and
study design
sample handling, chemical analysis 6 24 5000 30,000 120,000 high depending on chemicals measured
data analysis and integrated interpretation 3 12 5000 15,000 60,000 high depending on data volume
communication and dissemination 3 12 5000 15,000 60,000 low
SUM 120,000 450,000
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consultations
The stakeholder consultations namely the conference on the
proposed framework in Paris 2012 concluded that it is time to
intensify collaboration at European and international level and to
set up the necessary means for harmonisation of practices, to
optimise the investments made and to increase efﬁciency. The
conference recommended establishing the framework to enable a
European view to interpret and to communicate HBM data to
translate results into management measures, and to increasingly
use HBM for investigation of exposure to mixtures, and for the risk
assessment of REACH substances of less concern. It recommended
establishing an efﬁcient data exchange system integrating existing
HBM data to solve related data protection and ethical aspects and
to establish a European “host” agency for analytical quality as-
surance and data storage, or even for European wide data analysis.
EC and Member States should take steps to strengthen collabora-
tion with HES/HIS/Nutrition for increased monitoring efﬁciency
and Member States should consider the elaboration of a European
Research Infrastructure Consortium (ERIC) proposal to establish
the legal basis for an exchange platform.
Information exchange, guidance on optimum approaches and
priorities, and facilitation of tailor-made Member State action
(adherent to comparable standards) could be a key priority for the
European Commission. Options for collaboration and coordination
with European and international agencies dealing with aspects
related to surveillance or chemicals such as ECDC, SAICM, WHOFig. 2. Environmental Policy objective
Please cite this article as: Joas, A., et al., Policy recommendations and
human biomonitoring surveys. Environ. Res. (2014), http://dx.doi.orgshould be considered thoroughly. In the light of thousands of
chemicals on the market and coming to the market in short in-
tervals the prioritisation of substances could be one of the highest
priorities for a European platform, and in the light of lack of
knowledge about health impacts, the development of health based
threshold values should be prioritised and Member States should
be assisted in communication of results.
Sharing of efforts between involved experts in particular for
technology and method development and use of read-across to
speed up decision making and method development, and use of
environmental surveillance in substance prioritisation and setting
up of survey design should be promoted as well as read-across
from occupational exposure to general population, by starting
method development for general population when occupational
exposure observed.
The experts recommended to focus on the integration of HBM
in REACH authorisation procedures, and on the inclusion of new
substances/exposure sources (extent to concept of “civilisation
exposures”) and to take initiatives to develop intelligent solutions
facilitating more efﬁcient use of HBM on European scale (better
use of existing databases), pooled data, novel sampling strategies,
representative regions concept, method development, etc.). It was
recommended to foster multi-disciplinary collaboration, coopera-
tion and information exchange across all professions involved (in
particular epidemiologists, toxicologists, HBM experts) and to
support coupling of HBM, HES, HIS, environmental measurements,
cohort studies and research.s that can be supported by HBM.
cost implications for a more sustainable framework for European
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Improved use of biomonitoring data, including better access for
secondary use and better comparability is an important objective
in European environmental and health policies. Comparable
monitoring data on European scale are considered a key parameter
for effective use of HBM as policy tool.
In order to keep the advantages of the expertise in harmonised
HBM, acquired in the European pilot study by COPHES and DE-
MOCOPHES, there is need to establish a European framework that
will allow an efﬁcient and targeted use of the tool in future. The
pilot projects concluded that there is a clear need and beneﬁt of a
European framework to allow sustainable HBM in Europe.
In Europe responsibility for HBM is distributed to 28 Member
States, but approaches comparable to those established e.g. in the
USA and Canada are principally applicable as well. The proposed
concept with the two overarching infrastructural pillars:
1) EU HBM suggestion and coordination platform for prior-
itisation and guidance, and
2) HBM implementation and enforcement network,
presents a fully elaborated structure considered sustainable. It
is ambitious in terms of beneﬁts and willingness to collaborate,
but it can be realised in a stepwise approach. Starting point can be
a data storage and exchange system and a systematic information
exchange (platform) between involved authorities, developing
into an open-ended decision and management structure over
time.
Key tasks of the overarching structure would be guidance on
study protocols, data interpretation, communication and transla-
tion of results, data storage and management, funding and review
schemes. The virtual European platform for chemical monitoring
developed by JRC could serve as an appropriate platform also for
data storage HBM.Funding sources
COPHES was coordinated by BiPRO GmbH, Germany, with the
University of Leuven, Belgium and was funded by DG Research in
the Seventh Framework Programme (FP7/2007-2013).
DEMOCOPHES (LIFE09 ENV/BE/000410) was coordinated by the
Federal Public Service Health, Food Chain Safety and Environment,
Belgium and was jointly ﬁnanced by the European Commission
LIFEþ programme (50%) and national institutions in each parti-
cipating country.
For information on both projects as well as on the national co-
funding institutions: see http://www.eu-hbm.info/.Acknowledgements
We would like to thank in particular the work package leaders
of COPHES that contributed to the development of the concept and
the experts from Commission Services, Centers for Disease Control
and Prevention (CDC), Health Canada, WHO and Member State
authorities that contributed with presentations and discussion to
the further reﬁnement and development. We would also like to
thank all project partners of COPHES and DEMOCOPHES and other
research groups in the European Member States, other European
countries and countries worldwide that supported the project
with information and experience.1 http://www.cdc.gov/nchs/nhanes.htm
2 http://www23.statcan.gc.ca/imdb/p2SV.pl?
Function¼getSurvey&SDDS¼5071&lang¼en&db¼ imdb&adm¼8&dis¼2
Please cite this article as: Joas, A., et al., Policy recommendations and
human biomonitoring surveys. Environ. Res. (2014), http://dx.doi.orgReferences
Angerer, J., 2012. Strengths and limitations of HBM – yes we can!. Int. J. Hyg. En-
viron. Health 215, 96–97.
Angerer, J., Aylward, L.L., Hays, S.M., Heinzow, B., Wilhelm, M., 2011. Human bio-
monitoring assessment values: approaches and data requirements. Int. J. Hyg.
Environ. Health 214, 348–360.
Becker, K., Seiwert, M., Casteleyn, L., Joas, R., Joas, A., Biot, P., Aerts, D., Castaño, A.,
Esteban, M., Angerer, Jn, Koch, H.M., Schoeters, G., Den Hond, E., Sepai, O., Exley,
K., Knudsen, L.E., Horvat, M., Bloemen, L., Kolossa-Gehring, M., 2013. A sys-
tematic approach for designing a HBM pilot study for Europe. Int. J. Hyg. En-
viron. Health 217, 312–322.
Bergkvist, C., Lignell, S., Sand, S., Aune, M., Persson, M., Håkansson, H., Berglund, M.,
2010. A probabilistic approach for estimating infant exposure to environmental
pollutants in human breast milk. J. Environ. Monit. 12 (5), 1029–1036.
Bevan, R., Angerer, J., Cocker, J., Jones, K., Koch, H.M., Sepai, O., Schoeters, G.,
Smolders, R., Levy, L., 2012. Framework for the development and application of
environmental biological monitoring guidance values. Regul. Toxicol. Pharma-
col. 63, 453–460.
Bevan, R., Jones, K., Cocker, J., Assem, F.L., Levy, L.S., 2013. Reference ranges for key
biomarkers of chemical exposure within the UK population. Int. J. Hyg. Environ.
Health 216, 170–174.
Calafat, A.M., 2012. The U.S. National Health and Nutrition Examination Survey and
human exposure to environmental chemicals. Int. J. Hyg. Environ. Health 215,
99–101.
Casas, M., Chevrier, C., Hond, E.D., Fernandez, M.F., Pierik, F., Philippat, C., Slama, R.,
Toft, G., Vandentorren, S., Wilhelm, M., Vrijheid, M., 2013. Exposure to bromi-
nated ﬂame retardants, perﬂuorinated compounds, phthalates and phenols in
European birth cohorts: ENRIECO evaluation, ﬁrst human biomonitoring re-
sults, and recommendations. Int. J. Hyg. Environ. Health 216, 230–242.
Casteleyn L., Dumez B., Becker K., Kolossa-Gehring M., Den Hond E., Schoeters G.,
Castaño A., Koch H.M., Angerer J., Esteban M., Exley K., Sepai O., Bloemen L.,
Horvat M., Knudsen L.E., Joas A., Joas R., Biot P., Koppen G., Dewolf M-C., Kat-
sonouri A., Hadjipanayis A., Cerna M., Krskova A., Schwedler G., Fiddicke U.,
Nielsen J.K.S., Jensen J.F., Rudnai P., Kozepesy S., Mulcahy M., Mannion R., Gutleb
A.C., Fischer M.E., Ligocka D., Jakubowski M., Reis M.F., Namorado S., Lupsa I-R.,
Gurzau A.E., Halzlova K., Jajcaj M., Mazej D., Tratnik Snoj J., Posada M., Lopez E.,
Berglund M., Larsson K., Lehmann A., Crettaz P., Aerts D., 2014. A pilot study on
the feasibility of European harmonized human biomonitoring: challenges and
opportunities, Submitted to be included in this “Special issue”.
Centers for Disease Control and Prevention (CDC), 2010. National Report on Human
Exposure to Environmental Chemicals. Atlanta: CDC.
Cerna, M., Krskova, A., Cejchanova, M., Spevackova, V., 2012. Human biomonitoring
in the Czech Republic: an overview. Int. J. Hyg. Environ. Health 215, 109–119.
Commission of the European Communities, 2007. Mid Term Review of the Eur-
opean Environment and Health Action Plan 2004–2010, Communication from
the Commission to the Council, the European Parliament and the European
Economic and Social Committee, Brussels, 11.6.2007, COM (2007) 314 ﬁnal.
Conrad, A., Schulz, C., Seiwert, M., Becker, K., Ullrich, D., Kolossa-Gehring, M., 2010.
German environmental survey IV: children′‘s exposure to environmental to-
bacco smoke. Toxicol. Lett. 192, 79–83.
De Felip, E., Bianchi, F., Bove, C., Cori, L., D’Argenzio, A., D’Orsi, G., Fusco, M., Miniero,
R., Ortolani, R., Palombino, R., Parlato, A., Pelliccia, M.G., Peluso, F., Piscopo, G.,
Pizzuti, R., Porpora, M.G., Protano, D., Senofonte, O., Spena, S.R., Simonetti, A., di
Domenico, A., 2014. Priority persistent contaminants in people dwelling in
critical areas of Campania Region, Italy (SEBIOREC biomonitoring study). Sci.
Total Environ. 487, 420–435.
Egorov, A.I., Dalbokova, D., Krzyzanowski, M., 2013. Biomonitoring-based environ-
mental public health indicators. Methods Mol. Biol. 930, 275–293.
Esteban, M., Schindler, B.K., Koch, H.M., Jiménez-Guerrero, J.A., Koch, H.M., Angerer,
J., Rivas, T.C., Navarro, C., Schoeters, G., Den Hond, E., Bloemen, L.,Rosado, M.,
Gómez, S., Casteleyn, L., Kolossa-Gehring, M., Becker, K., Schoeters, G., Den
Hond, E., Bloemen, L., Sepai, O., Exley, K., Knudsen, L.E., Horvat, M., Joas, A., Joas,
R., Aerts, D., Biot, P., Borošová, D., Davidson, F., Dumitrascu, I., Fischer, M.E.,
Grander, M., Janasik, B., Jones, K., Kašparová, L., Larssen, T., Naray, M., Nielsen, F.,
Hohenblum, P., Pinto, R., Pirard, C., Plateel, G., Tratnik, J.S., Wittsiepe, J.et al.,
EQUAS Reference Laboratories, Castaño A., 2014. Mercury analysis in hair:
Comparability and quality assessment within the transnational COPHES/DE-
MOCOPHES project. Submitted to be included in this “Special issue”.
Fiddicke, U., Becker. K., Schwedler, G., Seiwert, M., Joas, R., Joas, A., Biot, P., Aerts, D.,
Casteleyn, L., Dumez, B., Castaño, A., Esteban, M., Angerer, J., Koch, H.M.,
Schoeters, G., Den Hond, E., Sepai, O., Exley, K., Knudsen, L.E., Horvat, M.,
Bloemen, L., Katsonouri, A., Hadjipanayis, A., Cerna, M., Krsková, A., Fangel
Jensen, J., Nielsen, J.K.S, Rudnai, P., Közepésy, S., Gutleb, A.C.o, Fischer M.E., Li-
gocka, D., Kamińska, J., Reis, F.M., Namorado, S., Lupsa I.R., Gurzau, A.E., Hal-
zlova, K., Mazej, D., Snoj Tratnik, J., Rivas, T.C., Gómez S., Berglund, M., Larsson,
K., Lehmann, A., Crettaz, P., Dewolf, M.C., Burns, D., Kellegher, A., Kolossa-
Gehring, M., 2014. Lessons learnt on recruitment and ﬁeldwork from a pilot
European human biomonitoring survey. Submitted to be included in this
“Special issue”.
Frederiksen, H., Jensen, T.K., Jorgensen, N., Boye Kyhl, H., Husby, S., Skakkebaek, N.
E., Main, K.M., Juul, A., Andersson, A.M., 2014. Human urinary excretion of non-
persistent environmental chemicals: an overview of Danish data collected be-
tween 2006–2012. Reproduction 147 (4), 555–565.cost implications for a more sustainable framework for European
/10.1016/j.envres.2014.10.012i
A. Joas et al. / Environmental Research ∎ (∎∎∎∎) ∎∎∎–∎∎∎16Fréry, N., Vandentorren, S., Etchevers, A., Fillol, C., 2012. Highlights of recent studies
and future plans for the French human biomonitoring (HBM) programme. Int. J.
Hyg. Environ. Health 215, 127–132.
Haines, D.A., Murray, J., 2012. Human biomonitoring of environmental chemicals –
early results of the 2007–2009 Canadian Health Measures Survey for males and
females. Int. J. Hyg. Environ. Health 215, 133–137.
Hays, S.M., Aylward, L.L., 2012. Interpreting human biomonitoring data in a public
health risk context using Biomonitoring Equivalents. Int. J. Hyg. Environ. Health
215, 145–148.
Hebels, D.G., Georgiadis, P., Keun, H.C., Athersuch, T.J., Vineis, P., Vermeulen, R.,
Portengen, L., Bergdahl, I.A., Hallmans, G., Palli, D., Bendinelli, B., Krogh, V.,
Tumino, R., Sacerdote, C., Panico, S., Kleinjans, J.C., de Kok, T.M., Smith, M.T.,
Kyrtopoulos, S.A., EnviroGenomarkers Project, C., 2013. Performance in omics
analyses of blood samples in long-term storage: opportunities for the ex-
ploitation of existing biobanks in environmental health research. Environ.
Health Perspect. 121, 480–487.
Hohenblum, P., 2012. Pollution gets personal! A ﬁrst population-based human
biomonitoring study in Austria. Int. J. Hyg. Environ. Health 215 (2), 176–179.
Jakubowski, M., Trzcinka-Ochocka, M., 2005. Biological monitoring of exposure:
trends and key developments. J. Occup. Health 47, 22–48.
Joas, R., Casteleyn, L., Biot, P., Kolossa-Gehring, M., Castano, A., Angerer, J., Schoeters,
G., Sepai, O., Knudsen, L.E., Joas, A., Horvat, M., Bloemen, L., 2012. Harmonised
human biomonitoring in Europe: activities towards an EU HBM framework. Int.
J. Hyg. Environ. Health 215, 172–175.
Joas, A., Polcher, A., Casteleyn, L., Biot, P., Aerts, D., Kolossa-Gehring, M., Castano, A.,
Angerer, J., Schoeters, G., Sepai, O., Knudsen, L.E., Horvat, M., Bloemen, l, Joas, R.,
2012. Harmonized Human Biomonitoring in Europe: Activities Towards an EU
HBM Framework. Issues in Toxicology No. 9: Biomarkers and Human Biomo-
nitoring, vol. 1. Ongoing Programs and Exposures, The Royal Society of Chem-
istry, Cambridge, UK, ISBN: 978-1-84973-241-3.
Keune, H., Morrens, B., Loots, I., 2008. Risk communication and human biomoni-
toring: which practical lessons from the Belgian experience are of use for the
EU perspective? Environ. Health 7 (Suppl 1), S11.
Knudsen, L.E., Merlo, D.F. (Eds.), 2012. Issues in Toxicology No. 9: Biomarkers and
Human Biomonitoring, vol. 1. Ongoing Programs and Exposures, The Royal
Society of Chemistry, Cambridge, UK, ISBN: 978-1-84973-241-3.
Kolossa-Gehring, M., 2012. Human biomonitoring: political beneﬁts – scientiﬁc
challenges. Int. J. Hyg. Environ. Health 215, 247–252.
Kolossa‐Gehring M;, Becker K., Fiddicke U., Schulz C., Conrad A., Schröter‐Kermani
C., Seiwert M., 2011. Biomonitoring as a key tool in environmental health,
the German approach. 〈http://www.milieu-en-gezondheid.be/resultaten/
2007-2011/studiedag 21-12-2011/abstract MK.pdf〉 (accessed April 8th).
Kolossa-Gehring, M., Becker, K., Conrad, A., Schroter-Kermani, C., Schulz, C., Seiwert,
M., 2012. Environmental surveys, specimen bank and health related environ-
mental monitoring in Germany. Int. J. Hyg. Environ. Health 215, 120–126.
Kyrtopoulos, S.A., 2013. Making sense of OMICS data in population-based en-
vironmental health studies. Environ. Mol. Mutagen. 54, 468–479.
Leventakou, V., Roumeliotaki, T., Martinez, D., Barros, H., Brantsaeter, A.L., Casas, M.,
Charles, M.A., Cordier, S., Eggesbo, M., van Eijsden, M., Forastiere, F., Gehring, U.,
Govarts, E., Halldorsson, T.I., Hanke, W., Haugen, M., Heppe, D.H., Heude, B.,
Inskip, H.M., Jaddoe, V.W., Jansen, M., Kelleher, C., Meltzer, H.M., Merletti, F.,
Molto-Puigmarti, C., Mommers, M., Murcia, M., Oliveira, A., Olsen, S.F., Pele, F.,
Polanska, K., Porta, D., Richiardi, L., Robinson, S.M., Stigum, H., Strom, M.,
Sunyer, J., Thijs, C., Viljoen, K., Vrijkotte, T.G., Wijga, A.H., Kogevinas, M., Vrij-
heid, M., Chatzi, L., 2014. Fish intake during pregnancy, fetal growth, and ge-
stational length in 19 European birth cohort studies. Am. J. Clin. Nutr. 99,
506–516.
Manno, M., Viau, C., in collaboration, w, Cocker, J., Colosio, C., Lowry, L., Mutti, A.,
Nordberg, M., Wang, S., 2010. Biomonitoring for occupational health risk as-
sessment (BOHRA). Toxicol. Lett. 192, 3–16.
Merlo, D.F., Agramunt, S., Anna, L., Besselink, H., Botsivali, M., Brady, N.J., Ceppi, M.,
Chatzi, L., Chen, B., Decordier, I., Farmer, P.B., Fleming, S., Fontana, V., Forsti, A.,
Fthenou, E., Gallo, F., Georgiadis, P., Gmuender, H., Godschalk, R.W., Granum, B.,
Hardie, L.J., Hemminki, K., Hochstenbach, K., Knudsen, L.E., Kogevinas, M., Ko-
vacs, K., Kyrtopoulos, S.A., Lovik, M., Nielsen, J.K., Nygaard, U.C., Pedersen, M.,
Rydberg, P., Schoket, B., Segerback, D., Singh, R., Sunyer, J., Tornqvist, M., van
Loveren, H., van Schooten, F.J., Vande Loock, K., von Stedingk, H., Wright, J.,
Kleinjans, J.C., Kirsch-Volders, M., van Delft, J.H., NewGeneris, C., 2014. Micro-
nuclei in cord blood lymphocytes and associations with biomarkers of exposure
to carcinogens and hormonally active factors, gene polymorphisms, and gene
expression: the NewGeneris cohort. Environ. Health Perspect. 122, 193–200.Please cite this article as: Joas, A., et al., Policy recommendations and
human biomonitoring surveys. Environ. Res. (2014), http://dx.doi.orgMørck, T.A., Nielsen, F., Nielsen, J.K., Siersma, V.D., Grandjean, P., Knudsen, L.E.,
2014a. PFAS concentrations in plasma samples from Danish school children and
their mothers. Chemosphere.
Mørck T.A., Nielsen F., Nielsen J.K., Jensen J.F., Hansen P.W., Hansen A.K., Chris-
toffersen L.N., Siersma V.D., Larsen I.H., Hohlmann L.K., Skaanild M.T., Freder-
iksen F., Biot P., Casteleyn L., Kolossa-Gehring M., Schwedler G., Den Hond E.,
Schoeters G., Castaño A., Esteban M., Angerer J., Koch H.M., Bloemen L., Exley K.,
Sepai O., Joas A., Joas R., Aerts D., Fiddicke U., Lopez A., Cañas A., Knudsen L.E.,
2014b. The Danish contribution to the European DEMOCOPHES project: a de-
scription of cadmium, cotinine and mercury levels in Danish mother-child pairs
and the perspectives of supplementary sampling and measurements (same
issue).
Papadopoulou, E., Caspersen, I.H., Kvalem, H.E., Knutsen, H.K., Duarte-Salles, T.,
Alexander, J., Meltzer, H.M., Kogevinas, M., Brantsaeter, A.L., Haugen, M., 2013.
Maternal dietary intake of dioxins and polychlorinated biphenyls and birth size
in the Norwegian Mother and Child Cohort Study (MoBa). Environ. Int. 60,
209–216.
Paustenbach, D., Galbraith, D., 2006. Biomonitoring and biomarkers: exposure as-
sessment will never be the same. Environ. Health Perspect. 114 (8), 1143–1149.
Pedersen, M., Schoket, B., Godschalk, R.W., Wright, J., von Stedingk, H., Tornqvist,
M., Sunyer, J., Nielsen, J.K., Merlo, D.F., Mendez, M.A., Meltzer, H.M., Lukacs, V.,
Landstrom, A., Kyrtopoulos, S.A., Kovacs, K., Knudsen, L.E., Haugen, M., Hardie, L.
J., Gutzkow, K.B., Fleming, S., Fthenou, E., Farmer, P.B., Espinosa, A., Chatzi, L.,
Brunborg, G., Brady, N.J., Botsivali, M., Arab, K., Anna, L., Alexander, J., Agramunt,
S., Kleinjans, J.C., Segerback, D., Kogevinas, M., 2013. Bulky dna adducts in cord
blood, maternal fruit-and-vegetable consumption, and birth weight in a Eur-
opean mother-child study (NewGeneris). Environ. Health Perspect. 121,
1200–1206.
Perharic, L., Vracko, P., 2012. Development of national human biomonitoring pro-
gramme in Slovenia. Int. J. Hyg. Environ. Health 215, 180–184.
Reis, M.F., Tedim, J., Aguiar, P., Miguel, J.P., Casteleyn, L., Joas, R., Van Tongelen, B.,
2007. Online integrated solution to collect data, generate information and
manage events in the human biomonitoring ﬁeld. Int. J. Hyg. Environ. Health.
210, 3–4.
Schindler, B., Esteban, K., Koch, M., Castano, A., Koslitz, S., Cañas, A., Casteleyn, L.,
Kolossa-Gehring, M., Schwedler, G., Schoeters, G., Den Hond, E., Sepai, O., Exley,
K., Bloemen, L., Horvat, M., Knudsen, L.E., Joas, A., Joas, R., Biot, P., Aerts, D.,
Lopez, A., Huetos, O., Katsonouri, A., Maurer-Chronakis, K., Kasparova, L., Vrbík,
K., Rudnai, P., Naray, M., Guignard, C., Fischer, M.E., Ligocka, D., Janasik, B., Reis,
M.F., Namorado, S., Pop, C., Dumitrascu, I., Halzlova, K., Fabianova, E., Mazej, D.,
Tratnik, J.S., Berglund, M., Jönsson, B., Lehmann, A., Crettaz, P., Frederiksen, H.,
Nielsen, F., McGrath, H., Nesbitt, I., De Cremer, K., Vanermen, G., Koppen, G.,
Wilhelm, M., Becker, K., Angerer, J., 2014. The European COPHES/DEMOCOPHES
project: towards transnational comparability and reliability of human biomo-
nitoring results. Int. J. Hyg. Environ. Health 217 (6), 653–666.
Schoeters, G., Den Hond, E., Colles, A., Loots, I., Morrens, B., Keune, H., Bruckers, L.,
Nawrot, T., Sioen, I., De Coster, S., Van Larebeke, N., Nelen, V., Van de Mieroop,
E., Vrijens, J., Croes, K., Goeyens, K., Baeyens, W., 2012. Concept of the Flemish
human biomonitoring programme. Int. J. Hyg. Environ. Health 215, 102–108.
Silins, I., Hogberg, J., 2011. Combined toxic exposures and human health: bio-
markers of exposure and effect. Int. J. Environ. Res. Public Health 8, 629–647.
Stayner, L.T., Pedersen, M., Patelarou, E., Decordier, I., Vande Loock, K., Chatzi, L.,
Espinosa, A., Fthenou, E., Nieuwenhuijsen, M.J., Gracia-Lavedan, E., Stephanou,
E.G., Kirsch-Volders, M., Kogevinas, M., 2014. Exposure to brominated trihalo-
methanes in water during pregnancy and micronuclei frequency in maternal
and cord blood lymphocytes. Environ. Health Perspect. 122, 100–106.
Vineis, P., van Veldhoven, K., Chadeau-Hyam, M., Athersuch, T.J., 2013. Advancing
the application of omics-based biomarkers in environmental epidemiology.
Environ. Mol. Mutagen. 54, 461–467.
Viso, A.C., Casteleyn, L., Biot, P., Eilstein, D., 2009. Human biomonitoring pro-
grammes and activities in the European Union. J. Epidemiol. Community Health
63, 623–624.
Vrijheid, M., Slama, R., Robinson, O., Chatzi, L., Coen, M., van den Hazel, P., Thomsen,
C., Wright, J., Athersuch, T.J., Avellana, N., Basagana, X., Brochot, C., Bucchini, L.,
Bustamante, M., Carracedo, A., Casas, M., Estivill, X., Fairley, L., van Gent, D.,
Gonzalez, J.R., Granum, B., Grazuleviciene, R., Gutzkow, K.B., Julvez, J., Keun, H.
C., Kogevinas, M., McEachan, R.R., Meltzer, H.M., Sabido, E., Schwarze, P.E.,
Siroux, V., Sunyer, J., Want, E.J., Zeman, F., Nieuwenhuijsen, M.J., 2014. The
human early-life exposome (HELIX): project rationale and design. Environ.
Health Perspect. 122, 535–544.cost implications for a more sustainable framework for European
/10.1016/j.envres.2014.10.012i
